Johnson & Johnson (JNJ)vsSolventum Corp. (SOLV)
JNJ
Johnson & Johnson
$255.88
-3.63%
HEALTHCARE · Cap: $615.36B
SOLV
Solventum Corp.
$88.55
+2.76%
HEALTHCARE · Cap: $14.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1085% more annual revenue ($97.93B vs $8.26B). JNJ leads profitability with a 21.5% profit margin vs 17.3%. SOLV appears more attractively valued with a PEG of 1.22. SOLV earns a higher WallStSmart Score of 60/100 (C).
JNJ
Buy57
out of 100
Grade: C
SOLV
Buy60
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 29 in profit
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Distress zone — elevated risk
Elevated debt levels
Revenue declined 3.0%
Earnings declined 91.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bull Case : SOLV
The strongest argument for SOLV centers on P/E Ratio, Return on Equity. Profitability is solid with margins at 17.3% and operating margin at 5.6%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SOLV
The primary concerns for SOLV are Altman Z-Score, Debt/Equity, Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SOLV is a declining play — different risk/reward profiles.
SOLV carries more volatility with a beta of 0.72 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
SOLV scores higher overall (60/100 vs 57/100), backed by strong 17.3% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Solventum Corp.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?